Nuwellis Advances Pediatric Expansion of Aquadex System Following FDA Pre-Submission Meeting
Key Insights
Nuwellis successfully completed an FDA pre-submission meeting to expand Aquadex SmartFlow System (search) labeling for pediatric patients weighing 5 kg and above, down from the current 20 kg minimum.
Multiple publications from leading pediatric centers over the past 10 years have demonstrated safe and effective use of Aquadex in patients weighing less than 20 kg.
The FDA provided constructive feedback on the regulatory pathway, including requirements for 510(k) submission supported by bench testing, toxicological assessments, and pediatric clinical evidence.
Nuwellis has successfully completed a pre-submission meeting with the U.S. Food and Drug Administration regarding the proposed label expansion of its Aquadex SmartFlow System (search) to support pediatric patients weighing 5 kg and above, representing a significant reduction from the currently cleared indication for patients weighing 20 kg and above.
Clinical Need and Safety Considerations
"In low-weight pediatric patients, fluid management is highly sensitive and requires careful clinical oversight," said Stuart Goldstein, M.D., Nuwellis' Director of Clinical Strategy. "The ability to monitor hematocrit change in real-time provides an important additional layer of safety and insight that can support more informed ultrafiltration decisions. This type of capability becomes particularly valuable in smaller patients, where traditional approaches may be more limited."
The proposed label update is intended to address a significant unmet need in low-weight pediatric patients with fluid overload (search) who require controlled ultrafiltration without the complexity of full renal replacement therapy.
Clinical Evidence and Real-World Experience
Over the past 10 years, multiple publications from leading pediatric centers have demonstrated the safe and effective use of Aquadex in patients weighing less than the currently indicated 20 kg. The repeated utilization in the 5-20 kg population and evidence has demonstrated the need for expanding the labeling to reflect its consistent use for these patients.
"Our work with leading pediatric centers has reinforced the importance of combining clinical experience with real-world evidence when evaluating therapies in this population. This includes extensive experience with both published and presented data validating the utility, and reinforcing the importance of expanding into this population," said Kelsey Newell, Nuwellis' Senior Director of Medical Affairs.
Regulatory Pathway and Timeline
The pre-submission meeting provided constructive feedback on the company's proposed regulatory strategy, including a pathway toward a 510(k) submission supported by targeted bench testing, toxicological assessments, and pediatric clinical evidence. The feedback provides important clarity as Nuwellis advances its regulatory and clinical plans in this high-need patient population.
The company anticipates submitting to the FDA by the end of 2026. Newell noted that this approach helps demonstrate how Aquadex can be used effectively within its intended ultrafiltration application, supported by clearly defined labeling and appropriate training and risk mitigation.
Strategic Impact
"By adjusting the labeling and aligning with one of our fastest growing patient categories, we are better positioned to support clinicians faced with this urgent need while growing this segment compliantly and increase our presence for efficacy and expansion," Newell added.
Innovation Portfolio Enhancement
In parallel developments, Nuwellis has received a Notice of Allowance from the U.S. Patent and Trademark Office (search) for a new patent covering its novel dual lumen midline catheter technology designed for use in ultrafiltration therapies. This next-generation catheter incorporates advanced design elements to optimize blood flow dynamics during therapy, including separate withdrawal and infusion lumens with pressure-balancing features that help maintain stable flow and reduce complications associated with fluid removal procedures.
"The allowed patent, 'Dual Lumen Catheter,' reflects Nuwellis' continued investment in innovation to improve fluid management solutions and expand the clinical utility of our Aquadex SmartFlow system (search)," said David Lerner, Nuwellis' CTO and the named inventor on the patent application. "Our team has focused on solving real-world clinical challenges in ultrafiltration therapy, and this technology reflects our commitment to improving both patient outcomes and clinician experience through thoughtful design and engineering."